Cornerstone Advisors (Washington)’s Myriad Genetics MYGN Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-140	Closed	-$4K	–	1175
2019 Q2	$4K	Hold	140	–	–	﹤0.01%	972
2019 Q1	$5K	Sell	140 -21	-13%	-$639	﹤0.01%	834
2018 Q4	$5K	Hold	161	–	–	﹤0.01%	774
2018 Q3	$7K	Hold	161	–	–	﹤0.01%	714
2018 Q2	$6K	Hold	161	–	–	﹤0.01%	701
2018 Q1	$5K	Buy	161 +21	+15%	+$711	﹤0.01%	706
2017 Q4	$5K	Hold	140	–	–	﹤0.01%	704
2017 Q3	$5K	Hold	140	–	–	﹤0.01%	698
2017 Q2	$4K	Hold	140	–	–	﹤0.01%	722
2017 Q1	$3K	Hold	140	–	–	﹤0.01%	753
2016 Q4	$2K	Hold	140	–	–	﹤0.01%	819
2016 Q3	$3K	Sell	140 -140	-50%	-$3.55K	﹤0.01%	746
2016 Q2	$9K	Hold	280	–	–	0.01%	440
2016 Q1	$10K	Hold	280	–	–	0.01%	422
2015 Q4	$12K	Hold	280	–	–	0.01%	410
2015 Q3	$10K	Buy	+280	New	+$9.94K	0.01%	450

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cornerstone Advisors (Washington)'s MYGN Position: Q3 2019 in Review

Cornerstone Advisors (Washington) sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 140 shares — an estimated $4K sold.

Cornerstone Advisors (Washington) first reported a position in MYGN in Q3 2015 and held it in 16 quarters. The position peaked at $12K in Q4 2015. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

Cornerstone Advisors (Washington) reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
Cornerstone Advisors (Washington) sold 140 Myriad Genetics shares in Q3 2019, an estimated $4K.
Cornerstone Advisors (Washington) first reported a position in Myriad Genetics in Q3 2015 and held it in 16 quarters.
Cornerstone Advisors (Washington)'s Myriad Genetics position peaked at $12K in Q4 2015.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2019, filed 23 Oct 2019.